Dr Reddys commissions mPEG alcohol manufacturing facility

Published: 17-Mar-2010
Manufacturing

Dedicated facility will operate to c-GMP standards

The Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories has successfully commissioned a commercial scale manufacturing facility for pharma grade mPEG alcohols at its Cuernavaca facility in Mexico. It represents a significant investment in a dedicated facility operated to c-GMP standards.

The new facility is capable of producing a wide range of molecular weight mPEGs and has a multitonne annual capacity. The mPEG alcohol manufactured in Mexico will be supplied to Dr. Reddy’s c-GMP facility in Mirfield, UK, where commercial scale activation is carried out.

mPEG alcohols are the key raw materials for Activated mPEG, extensively used for pegylation with biologic drugs and increasingly for peptides and small molecule pharmaceuticals. Dr. Reddy’s has officially branded its extensive range of Activated mPEGs under the name PEGtech.

PEGtech branding has been used to bring together a broad product range comprising a variety of activating groups and molecular weights (5-60 kDa), which are now fully supported by backward integration to the key starting materials. It furthermore highlights the company’s extensive experience in product development and GMP manufacture of the Activated mPEGs.

‘Our investment in the world class mPEG alcohol facility in Mexico underlines our commitment to the growing market for Activated mPEGs,’ said Satish Reddy, managing director and coo, Dr. Reddy’s, ‘By introducing the PEGtech brand, our customers can be assured of the same high quality standards and customer service as they develop their PEGylated biologic drugs or small molecules from the laboratory right through to commercial applications.’
See more

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Read more
Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company
  4. Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    The cross-pollination effect: how shared learnings bear fruit for drug sponsors This article explores how contract development and manufacturing organisations leverage the cross-pollination of knowledge to help drug sponsors overcome critical challenges in pharmaceutical development

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Manufacturing

GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025

As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite
Manufacturing

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment
Manufacturing

Breaking down silos and building in seamless scale

A Q&A with Kindeva's Tommy Schornak on the Bridgeton facility, Annex 1 compliance and scaling sterile injectable production
Manufacturing

Specialist products for boosting microbial EM protocol reliability spotlighted by AnalytiChem UK at Pharmig 2025

AnalytiChem UK (formerly Cherwell) to demonstrate products aimed at ensuring reliability and reducing risk in microbial EM. AnalytiChem’s new locking lid Twistlock plates ensure EM sample security throughout the microbial monitoring process
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The cross-pollination effect: how shared learnings bear fruit for drug sponsors

This article explores how contract development and manufacturing organisations leverage the cross-pollination of knowledge to help drug sponsors overcome critical challenges in pharmaceutical development
Subscribe now